epilepsy

News

Jazz builds in epilepsy with $1.3bn Actio acquisition

Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.

News

Lundbeck preps for key bexicaserin data around year-end

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

News

EpiWatch app detects major seizures with few false alarms

An Apple Watch patient monitoring app can help people with epilepsy reduce the risk of sudden death, with high sensitivity and a low false alarm rate.

R&D

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

News

Angelini CEO Sergio Marullo di Condojanni

Angelini seeks US beachhead with $4.1bn Catalyst buy

Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

Jazz builds in epilepsy with $1.3bn Actio acquisition

Lundbeck preps for key bexicaserin data around year-end

EpiWatch app detects major seizures with few false alarms

Why UCB bet a billion dollars on cell therapy for epilepsy

Angelini seeks US beachhead with $4.1bn Catalyst buy

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

epilepsy

Editor's Picks